(3R,3'R)-3-((3-chloro-5-fluorophenyl)amino)-1'-(1H-pyrazolo[3,4-d]pyrimidin-4-yl)-[1,3'-bipiperidin]-2-one

ID: ALA5206309

Chembl Id: CHEMBL5206309

PubChem CID: 168295624

Max Phase: Preclinical

Molecular Formula: C21H23ClFN7O

Molecular Weight: 443.91

Associated Items:

Names and Identifiers

Canonical SMILES:  O=C1[C@H](Nc2cc(F)cc(Cl)c2)CCCN1[C@@H]1CCCN(c2ncnc3[nH]ncc23)C1

Standard InChI:  InChI=1S/C21H23ClFN7O/c22-13-7-14(23)9-15(8-13)27-18-4-2-6-30(21(18)31)16-3-1-5-29(11-16)20-17-10-26-28-19(17)24-12-25-20/h7-10,12,16,18,27H,1-6,11H2,(H,24,25,26,28)/t16-,18-/m1/s1

Standard InChI Key:  COXQUJPRGLQAKZ-SJLPKXTDSA-N

Alternative Forms

  1. Parent:

    ALA5206309

    ---

Associated Targets(Human)

BTK Tclin Tyrosine-protein kinase BTK (8973 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID
CD69 Tchem Early activation antigen CD69 (107 Activities)
Activity TypeRelationActivity valueUnitsAction TypeJournalPubMed IddoiAssay Aladdin ID

Molecule Features

Natural Product: NoOral: NoChemical Probe: NoParenteral: No
Molecule Type: Topical: NoFirst In Class: NoBlack Box: No
Chirality: NoAvailability: NoProdrug: No

Drug Indications

MESH IDMESH Heading EFO IDsEFO TermsMax Phase for IndicationReferences

Mechanisms of Action

Mechanism of ActionAction Typetarget IDTarget NameTarget TypeTarget OrganismBinding Site NameReferences

Calculated Properties

Molecular Weight: 443.91Molecular Weight (Monoisotopic): 443.1637AlogP: 3.22#Rotatable Bonds: 4
Polar Surface Area: 90.04Molecular Species: NEUTRALHBA: 6HBD: 2
#RO5 Violations: 0HBA (Lipinski): 8HBD (Lipinski): 2#RO5 Violations (Lipinski): 0
CX Acidic pKa: 9.05CX Basic pKa: 3.89CX LogP: 2.67CX LogD: 2.66
Aromatic Rings: 3Heavy Atoms: 31QED Weighted: 0.64Np Likeness Score: -1.62

References

1. Hopkins BT, Bame E, Bell N, Bohnert T, Bowden-Verhoek JK, Bui M, Cancilla MT, Conlon P, Cullen P, Erlanson DA, Fan J, Fuchs-Knotts T, Hansen S, Heumann S, Jenkins TJ, Gua C, Liu Y, Liu Y, Lulla M, Marcotte D, Marx I, McDowell B, Mertsching E, Negrou E, Romanowski MJ, Scott D, Silvian L, Yang W, Zhong M..  (2021)  Utilizing structure based drug design and metabolic soft spot identification to optimize the in vitro potency and in vivo pharmacokinetic properties leading to the discovery of novel reversible Bruton's tyrosine kinase inhibitors.,  44  [PMID:34314938] [10.1016/j.bmc.2021.116275]

Source